Accessibility Menu
MiMedx Group Stock Quote

MiMedx Group (NASDAQ: MDXG)

$6.74
(0.0%)
+0.00
Price as of October 22, 2025, 9:35 a.m. ET

KEY DATA POINTS

Current Price
$6.74
Daily Change
(0.0%) +$0.00
Day's Range
$6.73 - $6.76
Previous Close
$6.74
Open
$6.76
Beta
1.26
Volume
576
Average Volume
652,739
Market Cap
997.2M
Market Cap / Employee
$6.74M
52wk Range
$5.59 - $10.14
Revenue
-
Gross Margin
0.81%
Dividend Yield
N/A
EPS
$0.22
CAPs Rating
-
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

MiMedx Group Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
MDXG+18.25%+5.64%+1.1%+32%
S&P+15.06%+95.03%+14.29%+420%

MiMedx Group Company Info

MiMedx Group, Inc. is a therapeutic biologics company, which engages in the design, manufacture, and marketing of products, and tissue processing services. It serves the wound care, burn, surgical, orthopedic, spine, sports medicine, ophthalmic, and dental sectors of healthcare. Its biomaterial platform technologies include AmnioFix and EpiFix, a tissue allografts derived from amnion and chorion layers of human placental membrane, EpiCord and AmnioCord, a tissue allografts derived from umbilical cord tissue, and AmnioFill, a placental connective tissue matrix derived from the placental disc and other placental tissue. The company was founded on July 30, 1985 and is headquartered in Marietta, GA.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$98.61M13.1%
Gross Profit$79.82M10.6%
Gross Margin80.95%-1.8%
Market Cap$902.46M-11.8%
Market Cap / Employee$1.08M0.0%
Employees837-6.5%
Net Income$9.62M-45.4%
EBITDA$15.53M-35.9%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$118.87M72.2%
Accounts Receivable$69.23M31.1%
Inventory24.9-0.7%

Liabilities

Q2 2025YOY Change
Long Term Debt$17.21M-5.7%
Short Term Debt$1.25M25.0%

Ratios

Q2 2025YOY Change
Return On Assets12.26%-30.3%
Return On Invested Capital-0.61%9.1%

Cash Flow

Q2 2025YOY Change
Free Cash Flow$14.24M-34.4%
Operating Free Cash Flow$14.42M-33.9%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Earnings10.1033.8128.1828.33140.06%
Price to Book4.807.815.784.45-32.25%
Price to Sales2.564.123.232.51-17.25%
Price to Tangible Book Value5.789.406.895.24-36.64%
Price to Free Cash Flow TTM16.0222.2517.3115.67-27.98%
Enterprise Value to EBITDA65.98113.9191.6552.2728.89%
Free Cash Flow Yield6.2%4.5%5.8%6.4%38.85%
Return on Equity62.5%25.0%22.3%16.6%-76.19%
Total Debt$19.02M$24.84M$18.66M$18.46M-4.09%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.